Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | IGF1R | P08069 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20485438 | 1.00 | KDM4E (0.71) | KDM4EUSP2MEN1KMT2AIGF1R | |
| SCHEMBL18587423 | 1.00 | KDM4E (0.71) | KDM4EUSP2MEN1KMT2AIGF1R | |
| SCHEMBL31419975 | 0.85 | KDM4E (0.73) | KDM4EUSP2MEN1KMT2AIGF1R | |
| SCHEMBL2950084 | 0.83 | KDM4E (0.71) | KDM4EUSP2MEN1KMT2AIGF1R | |
| SCHEMBL4261494 | 0.83 | KDM4E (0.71) | KDM4EUSP2MEN1KMT2AIGF1R | |
| SCHEMBL4071246 | 0.83 | KDM4E (0.71) | KDM4EUSP2MEN1KMT2AIGF1R | |
| SCHEMBL23610052 | 0.83 | KDM4E (0.71) | KDM4EMEN1KMT2AIGF1RGAA | |
| SCHEMBL17835877 | 0.83 | KDM4E (0.71) | KDM4EMEN1KMT2AIGF1RGAA | |
| SCHEMBL1460360 | 0.83 | KDM4E (0.71) | KDM4EMEN1KMT2AIGF1RGAA | |
| SCHEMBL4261489 | 0.78 | KDM4E (0.64) | KDM4EUSP2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3344630-B1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-09 | — | — | EP | disclosed |
| US-10314823-B2 | Substituted 1,2-dihydro-3H-pyrrolo[1,2-c]imidazol-3-one antibacterial compounds | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-06-11 | — | — | US | disclosed |
| US-20180250273-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-c]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | IDORSIA PHARMACEUTICALS LTD. (CH) | 2018-09-06 | — | — | US | disclosed |
| EP-3344630-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | Idorsia Pharmaceuticals Ltd (CH) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017037221-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10314823-B2 | Substituted 1,2-dihydro-3H-pyrrolo[1,2-c]imidazol-3-one antibacterial compounds | MRPL21, MRM1, MT-CO1 | KDM4E 2265/4885USP2 4611/4885MEN1 356/4885 |
| US-20180250273-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-c]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | MRPL21, MRM1, MT-CO1 | KDM4E 2265/4885USP2 4611/4885MEN1 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.